• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    6/23/23 9:12:35 AM ET
    $AHI
    $BBLN
    $BDRX
    $CFMS
    Package Goods/Cosmetics
    Consumer Discretionary
    Medical/Nursing Services
    Health Care
    Get the next $AHI alert in real time by email

    Gainers

    • Conformis (NASDAQ:CFMS) stock moved upwards by 90.6% to $2.21 during Friday's pre-market session. The market value of their outstanding shares is at $16.5 million.
    • OncoSec Medical (NASDAQ:ONCS) shares rose 84.82% to $0.39. The company's market cap stands at $2.3 million.
    • Surgalign Holdings (NASDAQ:SRGA) stock increased by 58.8% to $0.32. The market value of their outstanding shares is at $2.9 million.
    • SCWorx (NASDAQ:WORX) stock rose 32.14% to $0.47. The market value of their outstanding shares is at $6.1 million.
    • Renalytix (NASDAQ:RNLX) stock rose 12.37% to $2.38. The market value of their outstanding shares is at $111.5 million.
    • SQZ Biotechnologies (NYSE:SQZ) stock rose 11.9% to $0.58. The market value of their outstanding shares is at $17.1 million.

    Losers

    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock decreased by 15.8% to $0.07 during Friday's pre-market session. The company's market cap stands at $1.2 million.
    • Babylon Holdings (NYSE:BBLN) shares declined by 12.91% to $0.54. The market value of their outstanding shares is at $13.8 million.
    • Evelo Biosciences (NASDAQ:EVLO) stock declined by 9.43% to $0.14. The market value of their outstanding shares is at $15.1 million.
    • Beyond Air (NASDAQ:XAIR) shares fell 8.86% to $5.2. The company's market cap stands at $156.4 million. As per the press release, Q4 earnings came out yesterday.
    • Advanced Health (NASDAQ:AHI) stock fell 8.81% to $1.14. The company's market cap stands at $31.9 million.
    • MultiPlan (NYSE:MPLN) stock declined by 7.32% to $1.9. The market value of their outstanding shares is at $1.2 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHI
    $BBLN
    $BDRX
    $CFMS

    CompanyDatePrice TargetRatingAnalyst
    Beyond Air Inc.
    $XAIR
    7/17/2025$11.00Buy
    D. Boral Capital
    MultiPlan Corporation
    $MPLN
    6/26/2024$2.00Neutral
    Piper Sandler
    Beyond Air Inc.
    $XAIR
    6/25/2024Buy → Neutral
    BTIG Research
    Advanced Health Intelligence Ltd.
    $AHI
    5/30/2024Buy → Hold
    Maxim Group
    Biodexa Pharmaceuticals plc American Depositary Shs
    $BDRX
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    Beyond Air Inc.
    $XAIR
    7/28/2023$10.00Overweight
    Piper Sandler
    Beyond Air Inc.
    $XAIR
    6/15/2023$15.00Buy
    BTIG Research
    Babylon Holdings Limited
    $BBLN
    3/16/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $AHI
    $BBLN
    $BDRX
    $CFMS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 1, 2022 - FDA Roundup: July 1, 2022

    For Immediate Release: July 01, 2022 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a request for nominations for consumer representatives to serve on advisory committees and panels for which vacancies currently exist or are expected to occur in the near future. The FDA relies on our many advisory committees to help us

    7/1/22 11:54:25 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $AHI
    $BBLN
    $BDRX
    $CFMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman of the Board Lisi Steven A. bought $19,491 worth of shares (6,000 units at $3.25), increasing direct ownership by 0.18% to 3,327,411 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    7/23/25 4:05:39 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Director Carey Robert bought $250,050 worth of shares (1,000,000 units at $0.25), increasing direct ownership by 33% to 4,076,864 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    3/17/25 8:15:33 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Gaul Michael A. bought $2,294 worth of shares (6,000 units at $0.38), increasing direct ownership by 7% to 94,150 units (SEC Form 4)

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    2/21/25 5:00:14 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $AHI
    $BBLN
    $BDRX
    $CFMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AHI
    $BBLN
    $BDRX
    $CFMS
    SEC Filings

    View All

    SEC Form 4 filed by Chief Financial Officer Moorhead Daniel J

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:17:51 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Moorhead Daniel J

    3 - Beyond Air, Inc. (0001641631) (Issuer)

    1/6/26 4:15:38 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Lee Yoori

    4 - Beyond Air, Inc. (0001641631) (Issuer)

    11/24/25 5:22:10 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SCHEDULE 13G - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    2/17/26 9:55:22 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Beyond Air Inc.

    SCHEDULE 13G/A - Beyond Air, Inc. (0001641631) (Subject)

    2/17/26 4:58:35 PM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCWorx Corp.

    SCHEDULE 13G/A - SCWorx Corp. (0001674227) (Subject)

    2/17/26 10:51:29 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AHI
    $BBLN
    $BDRX
    $CFMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Beyond Air with a new price target

    D. Boral Capital initiated coverage of Beyond Air with a rating of Buy and set a new price target of $11.00

    7/17/25 8:02:31 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    Piper Sandler initiated coverage on MultiPlan with a new price target

    Piper Sandler initiated coverage of MultiPlan with a rating of Neutral and set a new price target of $2.00

    6/26/24 7:57:01 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Beyond Air downgraded by BTIG Research

    BTIG Research downgraded Beyond Air from Buy to Neutral

    6/25/24 8:04:46 AM ET
    $XAIR
    Medical/Dental Instruments
    Health Care

    $AHI
    $BBLN
    $BDRX
    $CFMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

    February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Ltd (Otsuka) for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours (GIST). The compound also has the potential to be useful

    2/4/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biodexa Announces Pricing of $10 Million Public Offering

    December 18, 2025 Biodexa Announces Pricing of $10 Million Public Offering Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX) ("Biodexa" or the "Company"), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a best efforts public offering of an aggregate of (i) 157,000 units (the "ADS Units"), with each unit consisting of (A) one American depositary share (representing 100,000 of the Company's ordinary shares) ("ADSs"), and (B) two Series L warrants, each to purchase one ADS (the "Series L Warrants"), and (ii) 2,891,781 pre-funded units (the "Pre-Funded Units"), with each Pre

    12/18/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $BBLN
    $BDRX
    $CFMS
    Financials

    Live finance-specific insights

    View All

    Claritev Reports Fourth Quarter and Full Year 2024 Results with Initial Guidance for Full Year 2025

    Q4 2024 Revenues of $232.1 million, Net Loss of $138.0 million and Adjusted EBITDA of $141.6 million Full Year 2024 Revenues of $930.6 million, Net Loss of $1,645.8 million and Adjusted EBITDA of $576.7 million Full Year 2025 Revenues guidance of (2)% to flat as compared to FY 2024 and FY 2025 Adjusted EBITDA % guidance of 62.5% to 63.5% Claritev Corporation ("Claritev" or the "Company") (NYSE:MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2024. Chairman, CEO and President Travis Dalt

    2/25/25 6:00:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    MultiPlan Corporation Announces Fourth Quarter and Full Year 2024 Earnings Conference Call

    MultiPlan Corporation ("MultiPlan" or the "Company") (NYSE:MPLN), a leading provider of technology and data solutions that improve affordability, quality and transparency in healthcare, announced today that it will release its fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, and hold its conference call that morning at 8:00 am Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique pin. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to: https://www.netroadsho

    1/28/25 8:30:00 AM ET
    $MPLN
    Business Services
    Consumer Discretionary

    Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

    CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs, has made significant progress in transforming itself from a drug delivery innovator to a therapeutics company with a focus on drugs to fight diabetes and cancer. Biodexa's strategy is not based on discovering new medicines; rather it looks to reduce the risk of failure in the clinic by re-purposing molecules with proven safety records for new indications. When Biodexa sees potential, it acquires these products from third parties under licensing agreements which generally call

    11/21/24 7:35:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $BBLN
    $BDRX
    $CFMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHI
    $BBLN
    $BDRX
    $CFMS
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions

    Tampa, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:WORX), a leading provider of data management and software solutions for the healthcare industry, today announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx's commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the developm

    9/3/25 11:44:49 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary